Gilead says Medicare negotiated price for Biktarvy set at $2,600 per 30-day supply from Jan. 1, 2028, an ~38% discount to list price; sees ~$1.5B hit in 2028

Gilead says the U.S. Medicare negotiated price for its HIV drug Biktarvy is set at $2,600 per 30-day supply from Jan. 1, 2028, an approximately 38% discount to the Medicare list price. Gilead sees about a $1.5 billion hit in 2028 from lower Biktarvy prices in Medicare.

Detected & updated continuously · Source: Nebula